Search Result

Results for "

glucocorticoid receptor antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Glucocorticoid Receptor (17) Akt (1) Androgen Receptor (5) Apoptosis (1) Autophagy (5) Calcium Channel (1) Drug Isomer (1) Endogenous Metabolite (4) ERK (1) Estrogen Receptor/ERR (2) Ferroptosis (1) FXR (1) G protein-coupled Bile Acid Receptor 1 (1) GABA Receptor (6) Glutathione Reductase (GR) (1) iGluR (6) Isotope-Labeled Compounds (7) Mineralocorticoid Receptor (8) mTOR (1) NF-κB (6) NO Synthase (5) p38 MAPK (1) Parasite (2) PI3K (1) PPAR (6) Progesterone Receptor (8) Reference Standards (5) Sigma Receptor (6) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (12) Cardiovascular Disease (8) Endocrinology (15) Infection (2) Inflammation/Immunology (9) Metabolic Disease (15) Neurological Disease (10)
Oligonucleotides:	Antisense Oligonucleotides (2)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Glucocorticoid Receptor SGK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13683

Mifepristone Maximum Cited Publications 71 Publications Verification RU486; RU 38486	Endogenous Metabolite Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (RU486) is a progesterone receptor (PR) and **glucocorticoid receptor** (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-111372

Finerenone 5+ Cited Publications BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease Metabolic Disease
Finerenone (BAY 94-8862) is a third-generation, selective, and orally active nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀ = 18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (> 500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-113416

Dehydroepiandrosterone sulfate 5 Publications Verification DHEA sulfate; Prasterone sulfate	GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-B0765

Dehydroepiandrosterone sulfate sodium 5 Publications Verification DHEA sulfate sodium; Prasterone sulfate sodium	GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-13702

Nilutamide Nilandron; RU 23908	Androgen Receptor Parasite	Infection Endocrinology Cancer
Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .

HY-117880

Exicorilant 2 Publications Verification CORT 125281	Glucocorticoid Receptor	Metabolic Disease Endocrinology
Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a K_i value of 7 nM . Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia .

HY-111372R

Finerenone (Standard) BAY 94-8862 (Standard)	Reference Standards Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone (Standard) is the analytical standard of Finerenone. This product is intended for research and analytical applications. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-15710

Cort108297	Glucocorticoid Receptor	Metabolic Disease Endocrinology
Cort108297 is a specific **glucocorticoid receptor** (GR) antagonist. Cort108297 has a high affinity for GRs with a K_i of 0.45 nM.

HY-15709

AL 082D06 4 Publications Verification D06; D-06	Glucocorticoid Receptor	Endocrinology
AL 082D06 is a selective, nonsteroidal glucocorticoid receptor (GR) antagonist with K_i of 210 nM.

HY-112710

ORIC-101	Glucocorticoid Receptor	Endocrinology Cancer
ORIC-101 is a highly potent and selective **glucocorticoid receptor** antagonist, with an EC₅₀ of 5.6 nM. Anti-cancer activity. ORIC-101 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR	Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-13683R

Mifepristone (Standard) Maximum Cited Publications 71 Publications Verification RU486 (Standard); RU 38486 (Standard)	Reference Standards Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone (Standard) is the analytical standard of Mifepristone. This product is intended for research and analytical applications. Mifepristone (RU486) is a progesterone receptor (PR) and **glucocorticoid receptor** (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-125558

PT150 ORG-34517	Glucocorticoid Receptor	Neurological Disease
PT150 (ORG-34517) is a competitive and orally active **glucocorticoid receptor** antagonist. PT150 shows neuroprotective effects. PT150 has the potential for the research of Parkinson’s disease .

HY-141921S

Dehydroepiandrosterone sulfate sodium-d6 DHEA sulfate sodium-d6; Prasterone sulfate sodium-d6	Isotope-Labeled Compounds GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate sodium salt-d₆ (DHEA sulfate sodium salt-d₆; Prasterone sulfate sodium salt-d₆) is the deuterium labeled Dehydroepiandrosterone sulfate sodium salt (HY-B0765). Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-159695A

IONIS-GCCRRx sodium ISIS 426115 sodium	Glucocorticoid Receptor	Metabolic Disease
IONIS-GCCRRx (ISIS 426115) sodium, a **glucocorticoid receptor** antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .

HY-13683S

Mifepristone-d3 RU486-d₃; RU 38486-d₃	Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-113416R

Dehydroepiandrosterone sulfate (Standard) 1 Publications Verification DHEA sulfate (Standard); Prasterone sulfate (Standard)	Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) (Standard) is the analytical standard of Dehydroepiandrosterone sulfate (HY-113416). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-113416AS

Dehydroepiandrosterone sulfate-d6 sodium dihydrate DHEA sulfate-d6 sodium dihydrate; Prasterone sulfate-d6 sodium dihydrate	Isotope-Labeled Compounds GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate sodium dihydrate-d₆ sodium dihydrate is the deuterium labeled Dehydroepiandrosterone sulfate sodium dihydrate. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium dihydrate is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium dihydrate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium dihydrate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium dihydrate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium dihydrate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-13683S2

Mifepristone-d6 RU486-d₆; RU 38486-d₆	Glucocorticoid Receptor Autophagy Endogenous Metabolite NO Synthase Progesterone Receptor Isotope-Labeled Compounds	Endocrinology Cancer
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a progesterone receptor (PR) and **glucocorticoid receptor** (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-111372A

(Rac)-Finerenone (Rac)-BAY 94-8862	Mineralocorticoid Receptor	Cardiovascular Disease
(Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold) .

HY-111372S

Finerenone-d3 BAY 94-8862-d₃	Mineralocorticoid Receptor	Others
Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-111372S1

Finerenone-d5 1 Publications Verification BAY 94-8862-d₅	Isotope-Labeled Compounds Mineralocorticoid Receptor	Cardiovascular Disease
Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal *mineralocorticoid receptor* (MR)** antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-125627

CP-394531	Glucocorticoid Receptor Androgen Receptor	Neurological Disease Metabolic Disease
CP-394531 is an efficient and highly selective non-steroidal glucocorticoid receptor (GR) antagonist, with a K_i value of 0.1 nM. CP-394531 has a weak binding to androgen receptor (AR) (K_i = 130 nM), and has almost no effect on progesterone receptor (PR) and estrogen receptors (ERα, ERβ). CP-394531 completely blocks the half-maximal agonistic effect induced by Dexamethasone (HY-14648G), with a K_if of 4.1 nM. CP-394531 can be used to study various diseases such as diabetes, obesity, depression, neurodegenerative diseases, glaucoma and Cushing's disease .

HY-159695

IONIS-GCCRRx ISIS 426115	Glucocorticoid Receptor	Metabolic Disease
IONIS-GCCRRx (ISIS 426115), a **glucocorticoid receptor** antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .

HY-125839

OP-3633	Glucocorticoid Receptor	Inflammation/Immunology Endocrinology
OP-3633 is a potent and selective steroidal glucocorticoid receptor (GR) antagonist with an IC₅₀ of 29 nM, with inhibition of GR transcriptional activity. OP-3633 exhibits low progesterone receptor (PR) agonism and androgen receptor (AR) antagonism .

HY-B0251S

Eplerenone-d3 Epoxymexrenone-d₃	Isotope-Labeled Compounds Mineralocorticoid Receptor Endogenous Metabolite	Cardiovascular Disease
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC₅₀ of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .

HY-123163

JNJ-1250132 RWJ-66826; RTI-6617-003	Progesterone Receptor Glucocorticoid Receptor Androgen Receptor Estrogen Receptor/ERR	Endocrinology Cancer
JNJ-1250132 (RWJ-66826) is an orally active and potent steroidal progesterone receptor (PR) antagonist, with an IC₅₀ of 1.3 nM. JNJ-1250132 inhibits binding of the receptor to DNA in vitro. JNJ-1250132 is a potent competitive inhibitor of binding to the human glucocorticoid receptor (GR) (IC₅₀=0.50 nM) and the rat androgen receptor (AR) (IC₅₀=5.6 nM), and was a weak inhibitor of binding to human Estrogen receptor (ER) (IC₅₀ >3000 nM) .

HY-117847

LLY-2707	Glucocorticoid Receptor	Neurological Disease Metabolic Disease
LLY-2707 is a selective glucocorticoid receptor (GR) antagonist. LLY-2707 is promising for research of diabetes and psychiatric disorders such as schizophrenia .

HY-167932

Mifepristone methochloride RU486 methochloride; RU 38486 methochloride	Progesterone Receptor	Endocrinology
Mifepristone (RU486) methochloride is a glucocorticoid antagonist that blocks peripheral glucocorticoid and progesterone receptors. Mifepristone methochloride has been shown to have minimal effects on intraocular pressure in treated rabbits. Mifepristone methochloride was developed as a water-soluble formulation to enhance ocular penetration of the drug.

HY-13702R

Nilutamide (Standard) Nilandron (Standard); RU 23908 (Standard)	Reference Standards Androgen Receptor Parasite	Infection Endocrinology Cancer
Nilutamide (Standard) is the analytical standard of Nilutamide. This product is intended for research and analytical applications. Nilutamide (Nilandron) is an orally active nonsteroidal androgen receptor antagonist with affinity for androgen receptors but not for progestogen, estrogen or glucocorticoid receptors. Nilutamide can be used to research prostate cancer. Nilutamide also has antischistosomal properties .

HY-108061

A-348441	Glucocorticoid Receptor	Metabolic Disease
A-348441 is a liver selective **glucocorticoid receptor** antagonist. A-348441 can reduce the glucose level in the liver. A-348441 can be used for the research of metabolic disease, such as type 2 diabetes .

HY-13683S1

Mifepristone-13C,d3 RU486-¹³C,d₃; RU 38486-¹³C,d₃	Isotope-Labeled Compounds Progesterone Receptor Glucocorticoid Receptor NO Synthase Autophagy	Endocrinology Cancer
Mifepristone- ¹³C,d₃ is the ¹³C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay . Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-B0765R

Dehydroepiandrosterone sulfate sodium (Standard) DHEA sulfate sodium (Standard); Prasterone sulfate sodium (Standard)	Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB	Neurological Disease Metabolic Disease Inflammation/Immunology
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt (Standard) is the analytical standard of Dehydroepiandrosterone sulfate sodium salt (HY-B0765). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-W950003

(Rac)-Finerenone-d5 (Rac)-BAY 94-8862-d₅	Isotope-Labeled Compounds Mineralocorticoid Receptor	Cardiovascular Disease
(Rac)-Finerenone-d₅ ((Rac)-BAY 94-8862-d₅) is the deuterium labeled (Rac)-Finerenone (HY-111372A). (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).

HY-111372B

(R)-Finerenone (R)-BAY 94-8862	Drug Isomer Mineralocorticoid Receptor	Cardiovascular Disease
(R)-Finerenone ((R)-BAY 94-8862) is the R-isomer of Finerenone (HY-111372). Finerenone is a third-generation selective, orally active, non-steroidal mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM). Compared with glucocorticoid receptors (GR), androgen receptors (AR), and progesterone receptors (AR), Finerenone shows good selectivity (> 500-fold). Finerenone has potential application prospects in studies of heart and kidney diseases, such as type 2 diabetes and chronic kidney disease .

HY-119080

CP8754	Progesterone Receptor	Endocrinology Cancer
CP8754 is an orally active, selective human *progesterone receptor* (hPR)** antagonist that blocks progesterone-mediated signaling pathways. CP8754 competitively inhibits the binding of [ ³H]-progesterone to hPR. And in vitro, CP8754 inhibits progesterone-dependent exogenous luciferase and endogenous alkaline phosphatase expression; while in vivo, CP8754 inhibits rabbit endometrial transformation. CP8754 does not significantly bind to human glucocorticoid receptors (hGR), *estrogen receptors* (hER), or rat androgen receptors (rAR)**. CP8754 can be used in the study of progesterone-related diseases such as breast cancer, endometriosis, uterine fibroids, and meningioma, as well as hormone-dependent tumors .

HY-179476

3-Oxochol-5-en-24-oic acid	Androgen Receptor Endogenous Metabolite	Inflammation/Immunology Cancer
3-Oxochol-5-en-24-oic acid is a rare bile acid produced by the intestinal microbiota. 3-Oxochol-5-en-24-oic acid is a potent antagonist of the human androgen receptor (hAR), with an IC₅₀ of 119.4 nM. 3-Oxochol-5-en-24-oic acid has no significant agonistic or antagonistic effects on estrogen receptors (ER) or glucocorticoid receptors (GR). 3-Oxochol-5-en-24-oic acid effectively inhibits the growth of prostate cancer cells. In animal models, it enhances the efficacy of anti-PD-1 therapy by regulating the differentiation of CD8 ⁺ T cells. 3-Oxochol-5-en-24-oic acid can be used for research on regulating host immunity and anti-tumor studies .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113416

Dehydroepiandrosterone sulfate 5 Publications Verification DHEA sulfate; Prasterone sulfate	Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	GABA Receptor Sigma Receptor iGluR PPAR NF-κB
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-B0765

Dehydroepiandrosterone sulfate sodium 5 Publications Verification DHEA sulfate sodium; Prasterone sulfate sodium	Classification of Application Fields Metabolic Disease Endogenous metabolite Disease Research Fields Steroids Source Classification	GABA Receptor Sigma Receptor iGluR PPAR NF-κB
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-N0910

Notoginsenoside Ft1 1 Publications Verification	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Terpenoids Other Diseases Plants Disease Research Fields Araliaceae Source Classification	PI3K mTOR Akt Apoptosis p38 MAPK ERK Transmembrane Glycoprotein Glutathione Reductase (GR) Estrogen Receptor/ERR Calcium Channel Ferroptosis G protein-coupled Bile Acid Receptor 1 FXR
Notoginsenoside Ft1 is an orally active bioactive saponin. Notoginsenoside Ft1 inhibits the PI3K/AKT/mTOR signaling pathway, activates the p38 MAPK and ERK1/2 signaling pathways, and increases the proportion of CD8 ⁺ T cells, thereby inducing apoptosis and lysosomal cell death in various cancer cells, and promoting angiogenesis. Notoginsenoside Ft1 causes vasodilation by activating glucocorticoid receptors (GR) and estrogen receptor beta (ERβ) in endothelial cells. Notoginsenoside Ft1 increases intracellular Ca ²⁺ accumulation, reduces cAMP levels by activating a signaling network mediated through P2Y₁₂ receptors, and promotes platelet aggregation, thereby exerting a procoagulant effect. Notoginsenoside Ft1 inhibits ferroptosis (ferroptosis) in renal tubular epithelial cells by activating the TGR5 receptor, thereby demonstrating a renal protective effect. Notoginsenoside Ft1 acts as a TGR5 agonist and an FXR antagonist to combat obesity and insulin resistance .

HY-113416R

Dehydroepiandrosterone sulfate (Standard) 1 Publications Verification DHEA sulfate (Standard); Prasterone sulfate (Standard)	Human Gut Microbiota Metabolites Microorganisms Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Source Classification	Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) (Standard) is the analytical standard of Dehydroepiandrosterone sulfate (HY-113416). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-B0765R

Dehydroepiandrosterone sulfate sodium (Standard) DHEA sulfate sodium (Standard); Prasterone sulfate sodium (Standard)	Structural Classification Endogenous metabolite Steroids Source Classification	Reference Standards GABA Receptor Sigma Receptor iGluR PPAR NF-κB
Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt (Standard) is the analytical standard of Dehydroepiandrosterone sulfate sodium salt (HY-B0765). This product is intended for research and analytical applications. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

Cat. No.	Product Name	Chemical Structure

HY-141921S

Dehydroepiandrosterone sulfate sodium-d6
Dehydroepiandrosterone sulfate sodium salt-d₆ (DHEA sulfate sodium salt-d₆; Prasterone sulfate sodium salt-d₆) is the deuterium labeled Dehydroepiandrosterone sulfate sodium salt (HY-B0765). Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

Dehydroepiandrosterone sulfate sodium-d6

Dehydroepiandrosterone sulfate sodium salt-d₆ (DHEA sulfate sodium salt-d₆; Prasterone sulfate sodium salt-d₆) is the deuterium labeled Dehydroepiandrosterone sulfate sodium salt (HY-B0765). Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium salt is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium salt has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium salt can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium salt participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium salt may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-13683S

Mifepristone-d3
Mifepristone-d₃ is the deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-113416AS

Dehydroepiandrosterone sulfate-d6 sodium dihydrate

Dehydroepiandrosterone sulfate sodium dihydrate-d₆ sodium dihydrate is the deuterium labeled Dehydroepiandrosterone sulfate sodium dihydrate. Dehydroepiandrosterone sulfate (DHEA sulfate; Prasterone sulfate) sodium dihydrate is a neurosteroid and the main secretion product of the adrenal gland. Dehydroepiandrosterone sulfate sodium dihydrate has both non-competitive antagonist activity of GABA_A receptor and agonist activity of σ₁ receptor. Dehydroepiandrosterone sulfate sodium dihydrate can partially penetrate the blood-brain barrier, inhibit GABA_A receptor-mediated chloride influx, enhance NMDA receptor activity through σ₁ receptors, exert anti-inflammatory, anti-glucocorticoid and antidepressant effects, and increase convulsive sensitivity. Dehydroepiandrosterone sulfate sodium dihydrate participates in neuroprotection, neurite growth regulation and catecholamine secretion regulation, and can be used in the study of depression, post-traumatic stress disorder (PTSD), Alzheimer's disease, etc. Dehydroepiandrosterone sulfate sodium dihydrate may also be a biomarker for cardiovascular disease mortality, and its concentration is independently and negatively correlated with mortality .

HY-13683S2

Mifepristone-d6
Mifepristone-d₆ is deuterated labeled Mifepristone (HY-13683). Mifepristone (RU486) is a progesterone receptor (PR) and **glucocorticoid receptor** (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay .

HY-111372S

Finerenone-d3

Finerenone-d3 is the deuterium labeled finerenone (HY-111372). Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-111372S1

Finerenone-d5

1 Publications Verification

Finerenone-d₅ (BAY 94-8862-d₅) is deuterium labeled Finerenone. Finerenone (BAY 94-8862) is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold). Finerenone has the potential for cardiorenal diseases research, such as type 2 diabetes mellitus and chronic kidney disease .

HY-B0251S

Eplerenone-d3
Eplerenone-d₃ is the deuterium labeled Eplerenone. Eplerenone (Epoxymexrenone) is a selective, competitive and oreally active aldosterone antagonist with an IC₅₀ of 138 nM. Eplerenone has low affinity for progesterone, androgen, estrogen and glucocorticoid receptors. Eplerenone can be used for hypertension and heart failure after myocardial infarction reserch .

HY-13683S1

Mifepristone-13C,d3

Mifepristone- ¹³C,d₃ is the ¹³C- and deuterium labeled Mifepristone. Mifepristone (RU486) is a progesterone receptor (PR) and glucocorticoid receptor (GR) antagonist with IC₅₀s of 0.2 nM and 2.6 nM in in vitro assay . Mifepristone-13C,d3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-W950003

(Rac)-Finerenone-d5

(Rac)-Finerenone-d₅ ((Rac)-BAY 94-8862-d₅) is the deuterium labeled (Rac)-Finerenone (HY-111372A). (Rac)-Finerenone ((Rac)-BAY 94-8862) is the racemate of Finerenone. Finerenone is a third-generation, selective, and orally available nonsteroidal mineralocorticoid receptor (MR) antagonist (IC₅₀=18 nM). Finerenone displays excellent selectivity versus glucocorticoid receptor (GR), androgen receptor (AR), and progesterone receptor (>500-fold).

Cat. No.	Product Name		Classification

HY-159695A

IONIS-GCCRRx sodium ISIS 426115 sodium		Antisense Oligonucleotides
IONIS-GCCRRx (ISIS 426115) sodium, a **glucocorticoid receptor** antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .

HY-159695

IONIS-GCCRRx ISIS 426115		Antisense Oligonucleotides
IONIS-GCCRRx (ISIS 426115), a **glucocorticoid receptor** antagonist, is a 2'-O-methoxyethyl (2'-MOE) antisense oligonucleotide (ASO) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks